Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Wedbush cut their FY2016 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued to investors on Tuesday. Wedbush analyst H. Behanna now forecasts that the brokerage will post earnings of ($6.16) per share for the year, down from their previous estimate of ($5.95). Wedbush has a “Outperform” rating and a $92.00 price objective on the stock. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q4 2016 earnings at ($1.71) EPS, Q1 2017 earnings at ($1.82) EPS, Q2 2017 earnings at ($1.93) EPS, Q3 2017 earnings at ($2.01) EPS, Q4 2017 earnings at ($2.09) EPS, FY2017 earnings at ($7.86) EPS, FY2018 earnings at ($8.50) EPS, FY2019 earnings at ($7.67) EPS and FY2020 earnings at ($4.62) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.53) by $0.11. During the same quarter in the prior year, the business posted ($1.03) EPS.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

A number of other research firms also recently weighed in on RARE. Jefferies Group set a $109.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Sunday, September 18th. Leerink Swann reissued an “outperform” rating and issued a $94.00 target price (up previously from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, September 20th. Canaccord Genuity set a $120.00 target price on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, September 20th. HC Wainwright reissued a “buy” rating and issued a $109.00 target price (up previously from $102.00) on shares of Ultragenyx Pharmaceutical in a research note on Sunday, September 25th. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $101.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, September 14th. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $95.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 78.72 on Thursday. The firm’s market cap is $3.10 billion. The firm has a 50-day moving average of $66.18 and a 200 day moving average of $63.65. Ultragenyx Pharmaceutical has a 1-year low of $46.52 and a 1-year high of $117.12.

In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $67.61, for a total value of $1,352,200.00. Following the completion of the transaction, the chief executive officer now directly owns 493,244 shares of the company’s stock, valued at approximately $33,348,226.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Shalini Sharp sold 24,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $71.20, for a total transaction of $1,708,800.00. Following the completion of the transaction, the chief financial officer now directly owns 69,387 shares of the company’s stock, valued at $4,940,354.40. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pacer Advisors Inc. purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth about $100,000. First Mercantile Trust Co. raised its position in Ultragenyx Pharmaceutical by 1.7% in the third quarter. First Mercantile Trust Co. now owns 2,339 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 39 shares during the last quarter. Springbok Capital Management LLC purchased a new position in Ultragenyx Pharmaceutical during the first quarter worth about $189,000. Prudential Financial Inc. purchased a new position in Ultragenyx Pharmaceutical during the third quarter worth about $245,000. Finally, DIAM Co. Ltd. purchased a new position in Ultragenyx Pharmaceutical during the second quarter worth about $177,000. 93.14% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.